Background: Hugan Buzure Granule (HBG) is a traditional prescription of Uygur nationality in China mainly used to treat liver cold, stomachache, spleen and rib pain, arthralgia, rheumatism and urinary system diseases. Its mechanism of action in treating acute kidney injury (AKI) continues to remain unconfirmed. This study’s objective was to investigate the pharmacodynamics and mechanism of HBG in the management of AKI. Methods: The damage to the kidney tissue was examined by using H&E (Hematoxylin-eosin) staining. The BUN (Blood Urea Nitrogen) and Cr (Creatinine) in serum were examined by biochemical kit. The content of ROS (Reactive oxygen species) in kidney tissue was determined by ROS frozen section staining, while the amount of MDA (Malondialdehyde), GSH (Glutathione), and the enzymes of CAT (Catalase) and SOD (Superoxide dismutase) were assessed by using a biochemical kit. The tissue apoptosis was seen by using the TUNEL assay. ELISA kit was utilized to assess the content of IL-6, TNF-\alpha, and IL-1\beta in serum. Immunohistochemistry and Western blot were utilized to identify the translation of proteins associated to the NLRP3/Caspase-1 pathway and the TLR4/NF-\kappaB pathway in various tissues. Results: HBG considerably improved the renal injury in mice and decreased their kidney coefficient in contrast with the Control group. Immunohistochemistry and Western blot demonstrated that the translation of NLRP3, Caspase-1, IL-18, IL-1\beta, TLR4, NF-\kappaB, IL-6, TNF-\alpha were down-regulated in HBG groups. Conclusions: HBG may have a protective effect against AKI through anti-oxidative stress, inhibition of apoptosis and reduction of serum inflammatory factor levels. The mechanisms involved inhibiting NLRP3/Caspase-1 pathway and TLR4/NF-\kappaB pathway.